A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Exclusion Criteria

• •Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:
• •* Myocardial infarction
• •* cardiac surgery or revascularization (CABG/PTCA)
• •* unstable angina
• •* unstable HF
• •* New York Heart Association (NYHA) Class III-IV
• •* transient ischemic attack (TIA) or significant cerebrovascular disease
• •* unstable or previously undiagnosed arrhythmia
• •Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency
• •Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 3X ULN
• •Total Bilirubin (TB) \>2 mg/dL (34.2 μmol/L)
• •History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis
• •Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors
• •Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance